Skip to main content
Premium Trial:

Request an Annual Quote

Mainz Biomed to Initiate Pivotal US Clinical Study for Colorectal Cancer Early Detection Test

NEW YORK – Mainz Biomed said Tuesday that it has received approval from an independent institutional review board for the trial protocol of its ReconAAsense study. The study, which will recruit 15,000 individuals across the US, is to evaluate the clinical performance of the firm's colorectal cancer early detection test in order to support a submission for review by the US Food and Drug Administration.

Mainz's ColoAlert assay combines analysis of DNA, mRNA, and fecal immunohistochemistry to identify cancer in asymptomatic individuals from a stool sample. The company currently markets the test across Europe and the United Arab Emirates.

In the new US study, Mainz aims to measure the test's sensitivity, specificity, positive predictive value, and negative predictive value in average-risk subjects for both CRC and its precursor, advanced adenomas.

Once enrollment commences, Mainz said ReconAAsense will continue until at least 73 evaluable subjects are diagnosed with colorectal cancer and at least 138 evaluable subjects are diagnosed with advanced adenoma. The firm anticipates reporting results in 2025.

The trial joins another recently announced effort, eAArly DETECT, which is a US extension of Mainz's European feasibility study, ColoFuture. The firm expects that effort, which is analyzing the potential of newly licensed biomarkers to improve ColoAlert even further, to complete enrollment early next year and report top-line results by the end of the first half of 2023. Based on the outcome, the company may pivot to include some or all of those additional biomarkers in ReconAAsense.

"We look forward to commencing the US regulatory approval process for our next-generation product and are passionate about bringing this easy-to-administer test to the US. In addition, we eagerly await results from the ColoFuture feasibility study, as the potential to include novel biomarkers to detect advanced adenomas will be a game changer for at-home CRC screenings," Mainz CEO Guido Baechler said in a statement.

The Scan

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.